Tandem Diabetes Care (TNDM) Share-based Compensation Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Share-based Compensation Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 8.37% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -28.31% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 8.20% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 13.19% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 4.11% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -0.59% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 17.13% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 36.49% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 3.40% |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn | -12.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.38% |
| Mar 31, 2026 | -9.59% |
| Sep 30, 2025 | 20.69% |
| Jun 30, 2025 | -34.78% |
| Mar 31, 2025 | 12.07% |
| Dec 31, 2024 | 26.46% |
| Sep 30, 2024 | -43.46% |
| Jun 30, 2024 | 43.92% |
| Mar 31, 2024 | -43.83% |
| Sep 30, 2023 | -180.69% |
| Jun 30, 2023 | 74.51% |
| Mar 31, 2023 | 10.13% |
| Dec 31, 2022 | 9.36% |
| Sep 30, 2022 | -55.92% |
| Jun 30, 2022 | 285.66% |
| Mar 31, 2022 | 22.57% |
| Dec 31, 2021 | 75.45% |
| Sep 30, 2021 | -49.57% |
| Jun 30, 2021 | 77.06% |
| Mar 31, 2021 | 121.46% |